I have covered AcelRx Pharmaceuticals (ACRX) before, so investors should view this as an update to my previous articles.
Well, that was one busy quarter for ACRX, wasn't it? Here is what happened since the last financial statements were issued:
- Grünenthal terminated the marketing agreements for Zalviso in the EU and some other territories.
- ACRX signed DSUVIA US distribution agreement for dental surgeons (potentially also paving the way for a replacement of Grünenthal)
- ACRX stepped out of the bidding war for Tetraphase Pharmaceuticals (TTPH) - after assuring an increased break-up